Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,403 across all filing types
Latest filing 2023-04-03 Regulatory Filings
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release announcing a specific corporate event: an exclusive license agreement between Innate Pharma and Takeda regarding antibodies for Celiac disease research. It details financial terms (upfront payment, milestones, royalties) and includes standard corporate boilerplate, forward-looking statements, and contact information. This type of announcement, detailing a significant business transaction (licensing/partnership) that impacts future financing or operations, fits best under the Capital/Financing Update (CAP) category, as it involves securing future revenue streams and structuring a major deal. While it is a press release, it is highly specific to a financing/licensing event, making CAP more precise than the general Regulatory Filings (RNS). It is not an earnings release (ER), a management discussion (MDA), or a formal regulatory filing like a 10-K or IR.
2023-04-03 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is explicitly titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces a significant business event: an exclusive licensing agreement between Innate Pharma and Takeda regarding an antibody program for Celiac disease. This type of announcement, detailing strategic partnerships, financial milestones ($5M upfront, up to $410M in milestones), and business development, is characteristic of a general corporate announcement rather than a formal regulatory filing like a 10-K, an Earnings Release (ER), or an Interim Report (IR). Since it is a press release announcing a major corporate transaction/partnership, it does not fit perfectly into the highly specific categories like DIV, CAP, or TAR (which usually implies a takeover bid). Given the nature of the announcement (a strategic business deal communicated via press release), the most appropriate general category for significant, non-standard corporate news that doesn't fit elsewhere is Regulatory Filings (RNS), which serves as a broad category for official corporate disclosures that aren't strictly financial reports or proxy materials. However, since the content is a detailed business development announcement, it is often classified as a general corporate update. Given the options, RNS is the best fit as a general regulatory/corporate announcement fallback, although it is not a standard SEC form. It is not an ER (no period results), not a CT (no Q&A), and not a CAP (it's a licensing deal, not pure financing). RNS is the most suitable catch-all for significant, non-standard corporate news releases.
2023-04-03 French
INNATE PHARMA S.A. 6-K
Foreign Filer Report
2023-03-23 English
Inside Information / News release on accounts, results
Earnings Release Classification · 1% confidence The document is explicitly titled "INNATE PHARMA REPORTS FULL YEAR 2022 FINANCIAL RESULTS AND BUSINESS UPDATE" and provides detailed consolidated financial results for the year ending December 31, 2022. It includes key financial highlights, pipeline updates, and corporate news typical of an annual performance review. Although it mentions the audit is in progress, the primary purpose and content align with a comprehensive annual report, which corresponds to the 10-K filing type in the US context, or the general Annual Report category provided. Since the document is very long (59,137 chars) and contains the full results, it is the report itself, not just an announcement of the report (which would be RPA/RNS). FY 2022
2023-03-23 English
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 1% confidence The document is titled "INNATE PHARMA PRESENTE SES RESULTATS FINANCIERS... POUR L'ANNEE 2022" and explicitly states, "Innate Pharma SA... annonce aujourd'hui ses résultats financiers consolidés au 31 décembre 2022. Les comptes consolidés sont joints au présent communiqué." This clearly indicates the release of annual financial results. Although it mentions the audit is in progress (footnote 1), the primary purpose is the announcement of the full-year financial performance for 2022. This aligns best with the Annual Report (10-K) category, which covers full yearly performance. However, since the text is a press release announcing the results and mentioning that the consolidated accounts are *attached* (implying the full 10-K might be a separate filing or this is the preliminary release), and given the comprehensive nature covering R&D pipeline updates alongside financials, it strongly resembles an Earnings Release (ER) or a detailed Management Discussion and Analysis (MDA) combined with financial highlights. Since it provides the full financial highlights for the year and discusses business trends and outlook extensively, it fits the description of an Earnings Release (ER) or a Management Report (MDA). Given the structure focusing heavily on financial highlights and pipeline progress for the full year, and the mention of a conference call, 'ER' (Earnings Release) is a strong candidate for the initial announcement of annual results, even if it contains more detail than a typical quarterly ER. If the document were the actual 10-K filing, it would likely be structured differently. Since it is a press release announcing the results and providing key figures, 'ER' is the most appropriate classification among the choices for a major periodic financial announcement. Revisiting the definitions: '10-K' is the official yearly report. 'ER' is the initial announcement of periodical financial results (key highlights only). This document contains key highlights and financial figures for the year 2022, along with extensive pipeline updates. It is the official announcement made on March 23, 2023, for the year ended December 31, 2022. This is the primary mechanism for announcing annual results before or alongside the formal 10-K filing. Given the context of a press release format announcing the results, ER is the best fit over 10-K (which is the formal SEC document itself). FY 2022
2023-03-23 French
INNATE PHARMA S.A. 6-K
Foreign Filer Report
2023-03-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.